Skip to main content

Simpson Thacher & Bartlett and Anderson Mori & Tomotsune have represented Blackstone in its 242 billion yen ($2.3 billion) acquisition of Takeda Consumer Healthcare, which turned to Nishimura & Asahi for advice. The deal is expected to close in March 2021.

Takeda Consumer Healthcare is a subsidiary of Takeda Pharmaceutical and a leading provider of over the counter (OTC) medicines in Japan.

According to Reuters, Takeda Pharmaceutical has been selling its OTC assets worldwide as it seeks to refocus its business and reduce debt from last year’s $59 billion acquisition of Shire.

The deal marks Blackstone’s second private equity transaction in Japan’s healthcare sector, following the acquisition of AYUMI Pharmaceutical in 2019.

Simpson Thacher partners Tony King, Shahpur Kabraji and Jonathan Goldstein led on the transaction. Meanwhile, the Nishimura team was led by partners Yo Ota, Hiroko Shibata and Taeko Morita.

To contact the editorial team, please email ALBEditor@thomsonreuters.com.

Related Articles

Deals

Davis Polk, Gibson Dunn advise on $2.3 bln Nippon Paint-AOC deal

by Asian Legal Business《亚洲法律杂志》 |

Davis Polk & Wardwell has advised Japanese paint manufacturer Nippon Paint on its $2.3 billion acquisition of U.S. chemicals formulator AOC from Lone Star Funds, which was represented by Gibson, Dunn & Crutcher.

Deals

Stephenson Harwood, Links advise on $349 mln SG-UK taxi deal

by Asian Legal Business《亚洲法律杂志》 |

Stephenson Harwood has advised Singaporean transport operator ComfortDelGro on its 269-million-pound ($349 million) acquisition of the British private hire cab and courier company Addison Lee, whose shareholders were represented by Linklaters.

Deals

NO&T, STB, AMT, Davis Polk advise on Japan's biggest IPO in 6 years

by Asian Legal Business《亚洲法律杂志》 |

Nagashima Ohno & Tsunematsu and Simpson Thacher & Bartlett have advised Tokyo Metro on its 348.6 billion yen ($2.3 billion) initial public offering, Japan's largest in six years.